Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Immuneering Corp (IMRX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-23
$3.73-2.10%
Close 2026-10-23 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | — | 0 |
| EPS | — | -0.339 |
| Annual ending 2026-12-31 | ||
| Revenue | — | 21.27M |
| EPS | — | -1.119 |
| Annual ending 2027-12-31 | ||
| Revenue | — | 22.75M |
| EPS | — | |
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Extend cash runway to fund operations into 2029 | It aims to fund operations through 2029. | Intact | Cash runs out before end of 2029 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 5 of last 5 quarters. Cash, cash equivalents and marketable securities were $198.6 million at 2026-Q1 and $182.7 million at 2026-Q2. Management consistently expects the cash runway to fund operations into 2029, reflecting delivery on this financial stability priority. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage biotech exposure, not an established earnings compounder. The long-term thesis is in a watch state: the Phase 3 trial is advancing, but recent financial performance is weak, the company is loss-making, and overall risk is elevated.
The snapshot provides no valuation or market-expectations data, so whether IMRX looks cheap or expensive versus peers cannot be assessed. It does show weak recent performance and a recent earnings miss, but does not quantify what investors already expect.
Near term, the next report carries elevated execution risk: the stated miss probability is 47%, and the company operates in an industry with a high miss rate. Management says cash is expected to fund operations into 2029, though reported cash and marketable securities declined from $198.6 million in the first quarter of 2026 to $182.7 million in the second quarter. The Phase 3 MAPKeeper 301 trial was recruiting and dosing on schedule as of the second quarter, and management presented median overall survival data of 17.3 months from 55 Phase 2a patients.
The multi-year thesis hinges on continued progress in MAPKeeper 301 and stronger evidence that atebimetinib benefits pancreatic cancer patients. Near-term guidance cuts could add pressure to the already weak fundamental picture, while strong results and higher guidance from healthcare peers could support sector momentum. The snapshot also flags weakening jobs data as a possible source of pressure across cyclical names and healthcare stocks.
Over the next 1 to 3 years, IMRX remains a high-risk, trial-dependent story with meaningful clinical progress but weak recent financial performance and limited room for execution setbacks. The evidence is mixed, and valuation expectations are not provided. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management figures unavailable.
Advance Phase 2a trial of atebimetinib in pancreatic cancer | Immuneering is advancing its pancreatic cancer drug in Phase 2a trials. | Intact | Trial data fails to show efficacy or progress stalls in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Improve earnings toward reducing losses | A supporting condition in Immuneering Corp's published investment case. The stated target is EPS loss narrows from -$1.14 in 2026 to less negative in 2027. | Under Pressure | EPS loss worsens beyond -$1.34 in 2027 | Diluted EPS: $-0.27 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$1.14 in 2026 to less negative in 2027. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-0.27 USD/share · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: dfd71dc9-cbc9-4506-9586-09fa0b5bd289. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.29 → $-1.26 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-25 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-26 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-27 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-28 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-07-29 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-07-30 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-07-31 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-01 | $-1.29 | $19,500,000 | 5 / 7 |
| 2026-08-02 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-03 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-04 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-05 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-06 | $-1.29 | $19,500,000 | 7 / 7 |
| 2026-08-07 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-08 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-09 | $-1.30 | $27,300,000 | 8 / 5 |
| 2026-08-10 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-12 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-13 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-14 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-15 | $-1.31 | $19,500,000 | 5 / 7 |
| 2026-08-16 | $-1.31 | $19,500,000 | 6 / 7 |
| 2026-08-17 | $-1.31 | $19,500,000 | 6 / 7 |
| 2026-08-18 | $-1.31 | $19,500,000 | 6 / 7 |
| 2026-08-19 | $-1.31 | $19,500,000 | 6 / 7 |
| 2026-08-20 | $-1.27 | $17,062,500 | 7 / 8 |
| 2026-08-21 | $-1.27 | $17,062,500 | 7 / 8 |
| 2026-08-22 | $-1.29 | $17,062,500 | 7 / 8 |
| 2026-08-23 | $-1.29 | $17,062,500 | 7 / 8 |
| 2026-08-24 | $-1.29 | $17,062,500 | 7 / 8 |
| 2026-08-25 | $-1.29 | $17,062,500 | 7 / 8 |
| 2026-08-26 | $-1.29 | $19,500,000 | 7 / 8 |
| 2026-08-27 | $-1.29 | $19,500,000 | 7 / 8 |
| 2026-08-28 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-08-29 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-08-30 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-08-31 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-09-01 | $-1.26 | $22,750,000 | 7 / 8 |
| 2026-09-02 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-03 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-04 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-05 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-06 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-07 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-08 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-09 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-10 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-11 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-12 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-13 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-14 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-15 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-16 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-17 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-18 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-19 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-20 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-21 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-22 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-23 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-24 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-25 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-26 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-27 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-28 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-29 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-09-30 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-01 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-02 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-03 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-04 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-05 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-06 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-07 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-08 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-09 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-10 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-11 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-12 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-13 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-14 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-15 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-16 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-17 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-18 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-19 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-20 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-21 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-22 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-23 | $-1.26 | $22,750,000 | 6 / 7 |
| 2026-10-24 | $-1.26 | $22,750,000 | 6 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.